Parallel Advisors’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$231K Buy
4,821
+145
+3% +$6.35K ﹤0.01% 1092
2025
Q4
$181K Buy
4,676
+153
+3% +$5.83K ﹤0.01% 1142
2025
Q3
$160K Buy
4,523
+35
+0.8% +$1.27K ﹤0.01% 1169
2025
Q2
$162K Buy
4,488
+65
+1% +$2.15K ﹤0.01% 1108
2025
Q1
$138K Buy
4,423
+798
+22% +$25.3K ﹤0.01% 1133
2024
Q4
$92.5K Buy
3,625
+1,144
+46% +$30.3K ﹤0.01% 1313
2024
Q3
$70.2K Buy
2,481
+757
+44% +$21K ﹤0.01% 1434
2024
Q2
$45.5K Sell
1,724
-1,331
-44% -$36.9K ﹤0.01% 1580
2024
Q1
$92.8K Buy
3,055
+173
+6% +$5.1K ﹤0.01% 1204
2023
Q4
$81K Buy
2,882
+1,111
+63% +$30.5K ﹤0.01% 1204
2023
Q3
$48.1K Buy
1,771
+652
+58% +$19.4K ﹤0.01% 1414
2023
Q2
$34.4K Buy
1,119
+215
+24% +$7.28K ﹤0.01% 1588
2023
Q1
$32.6K Buy
904
+741
+455% +$27.5K ﹤0.01% 1597
2022
Q4
$6.44K Sell
163
-214
-57% -$8.93K ﹤0.01% 2216
2022
Q3
$15K Buy
377
+203
+117% +$8.67K ﹤0.01% 1818
2022
Q2
$7K Sell
174
-120
-41% -$4.92K ﹤0.01% 2144
2022
Q1
$11K Buy
294
+34
+13% +$1.33K ﹤0.01% 1982
2021
Q4
$10K Buy
260
+225
+643% +$8.74K ﹤0.01% 2120
2021
Q3
$1K Buy
+35
New +$1.36K ﹤0.01% 2943

Other funds holding RPRX

Parallel Advisors's RPRX Position: Q1 2026 in Review

Parallel Advisors increased its Royalty Pharma (RPRX) stake by 3.1% in Q1 2026, buying an estimated $6.35K and bringing the position to 4,821 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

Parallel Advisors first reported a position in RPRX in Q3 2021 and has held it in 19 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Parallel Advisors held 4,821 shares of Royalty Pharma worth $231K as of Q1 2026.
  • Parallel Advisors bought 145 Royalty Pharma shares in Q1 2026, an estimated $6.35K.
  • Royalty Pharma made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1092 holding.
  • Parallel Advisors first reported a position in Royalty Pharma in Q3 2021 and has held it in 19 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.